...

Relevant search

    Medicines

    In Line Products
    Coniel®

    Product: Coniel®(Benidipine Hydrochloride Tablets)

    Indication: CONIEL®is indicated for hypertension and Angina pectoris.

    Coniel®
    NESP®

    Product: NESP®(darbepoetin α Injection)

    Indication: For the treatment of anemia in adults with Chronic Kidney Disease ( CKD ) receiving hemodialysis.

    NESP®
    TAUROLITE®

    Product: TAUROLITE®(Tauroursodeoxycholic Acid Capsules)

    Indication: Dissolution of cholesterol stones:

    1. Presence of 1 or more cholesterol stones less than 2 cm in diameter visible on X-ray in the gallbladder or bile duct;

    2. Refusal of surgical treatment or unsuitable for surgical treatment;

    3. Cholesterol supersaturation confirmed by duodenal cannula bile test.

    TAUROLITE®
    Contractubex®

    Product: Contractubex®(Compound Heparin Sodium and Allantoin Gel)

    Indication: Hypertrophic and keloidal scars, movement restricting and cosmetically disfiguring scars after operations, amputations, burns and accidents; contractures such as Dupuytren's contracture and traumatic tendon contracture, cicatricial strictures.

    Contractubex®
    Xenical®

    Product: Xenical®(Orlistat Capsules)

    Indication: This product combined with a low calorie diet is suitable for long-term treatment of obese and overweight people,including those who have obesity related risk factors.This product has long-term effect of weight control (weight loss, weight maintenance and prevention of weight rebound).Taking this product can reduce the incidence rate of obesity related risk factors and other obesity related diseases, including hypercholesterolemia, type 2 diabetes, impaired glucose tolerance, hyperinsulinemia, hypertension, and reduce the fat in organs.

    Xenical®
    Xenical®

    Product: Xenical®OTC(Orlistat Capsules)

    Indication:Treatment of Obese or Overweight Patients (BMI > 24).

    Xenical®
    Flivas®

    Product: Flivas®(Naftopidil Tablets)

    Indication:Flivas® is indicated for the treatment of dysuria accompanying benign prostatic hyperplasia. Flivas® improves the symptoms of difficulty in urination, nocturia, and incomplete emptying by decreasing urethral pressure.

    Flivas®
    Glypressin®

    Product: Glypressin®(Terlipressin for Injection)

    Indication: Glypressin®is indicated in the treatment of bleeding esophageal varices.

    Glypressin®
    Hepa-Merz®

    Product: Hepa-Merz®(Ornithine Aspartate Injection)

    Indication: For the treatment of Hyperammonemia due to acute or chronic liver disease (e.g., all types of hepatitis, cirrhosis, fatty liver, post-hepatitis syndrome) and of hepatic encephalopathy, such as underlying or episodic hepatic encephalopathy with or secondary to impaired hepatic detoxification (e.g., cirrhosis), especially for the treatment of early hepatic coma or hepatic coma in a state of unconsciousness.

    Hepa-Merz®
    Pipeline products
    Product
    Indications Regions Partners Type of Collaboration Pre-Clinical Phase I Phase II Phase III NDA Launch
    RAVICTI®
    UCDs Greater China, S.Korea,SE Asia Greater China Immedica Pharma AB License and Development
    RAVICTI®

    EMA approved indication: RAVICTI® is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI® must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).

    Diacerein
    EB Greater China Twi License and Development
    Diacerein

    Waiting for Release......

    The information on this page is for introduction only. Please refer to the latest version of the drug specification approved by the National Medical Products Administration (NMPA) for detailed information. The drug information on this website shall not be used as a substitute for medical advice and medical consultation provided by qualified physicians or other qualified medical professionals, and shall not be used for the diagnosis of the disease. Please click OK to enter.

    OK

    This website uses cookies to improve website functionality. You may delete or block cookies by accessing your preferences. For more information please read here.